14 February 2018 - - US-based cancer care-focused company Puma biotechnology, Inc. (NASDAQ: PBYI) has entered into an exclusive agreement with Israel-based global healthcare companies partner Medison Pharma Ltd under which Medison will commercialize Nerlynx (neratinib) in Israel, the company said.
Nerlynx is not approved currently for commercialisation outside of the United States. Medison will be responsible for seeking the requisite regulatory approval and, once approved, for commercializing Nerlynx in Israel. Puma will receive upfront and milestone payments throughout the term of this agreement, as well as significant double digit royalties on Nerlynx sales in Israel.
Neratinib was approved by the US Food and Drug Administration in July 2017 for the extended adjuvant treatment of adult patients with early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy, and is marketed in the United States as Nerlynx (neratinib) tablets.
Puma biotechnology is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
Medison, backed by three generations of experience in the healthcare industry, has built and maintained long-standing relations with HMOs, local medical centers, and physicians.
It is uniquely qualified to provide the complete spectrum of integrated services for international companies looking to enter or expand their presence in the Israeli market.